Biogen Inc. (BIIB)
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody.
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024.
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodman - Leerink Partners Marc Goodman Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America.
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 45th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen.
